New data from a trial presented at the American Heart Association Scientific Sessions 2023 suggest use of aspirin in patients with a fully magnetically levitated left ventricular assist device (LVAD) is putting patients at an unnecessary bleeding risk. Results of the trial, which compared use of aspirin against nonuse in patients undergoing LVAD implantation with the HeartMate 3 pump and receiving a vitamin K antagonist, suggest those not taking aspirin had a rate of bleeding 33% less than those taking aspirin, which results in 47% reduction in days in the hospital among this patient population. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more